Acorda Therapeutics (ACOR) rumor spreaders are out in force. They are misleading the uninformed investors about a statement Biogen (BIIB) just made at a conference.
We have taken partial profits on Acorda at $30.20.
Our highest short tranche in Acorda is from $33.48.
The rumor related to Biogen buying Acorda is proven false. However, we are exiting Acorda with profit at $31.16 in the interest of defensive trading.
With this cover, we will exit the position completely.
If there are new actionable signals on Acorda, we will provide those in real-time to subscribers.
30 day free trial subscriptions are available.
